Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: Implications for application to clinical testing by Berg, Jonathan S. et al.
Next generation massively parallel sequencing of targeted
exomes to identify genetic mutations in primary ciliary
dyskinesia: implications for application to clinical testing
Jonathan S. Berg, MD, PhD1,2, James P. Evans, MD, PhD1,2, Margaret W. Leigh, MD3,
Heymut Omran, MD4, Chris Bizon, PhD5, Ketan Mane, PhD5, Michael R. Knowles, MD2,
Karen E. Weck, MD1,6, and Maimoona A. Zariwala, PhD6
1Department of Genetics, UNC Chapel Hill
2Department of Medicine, UNC Chapel Hill
3Department of Pediatrics, UNC Chapel Hill
4Department of Paediatrics and Adolescent Medicine, University Hospital, Freiburg, Germany
5The Renaissance Computing Institute, UNC Chapel Hill
6Department of Pathology and Laboratory Medicine, UNC Chapel Hill
Abstract
PURPOSE—Advances in genetic sequencing technology have the potential to enhance testing
for genes associated with genetically heterogeneous clinical syndromes, such as primary ciliary
dyskinesia (PCD). The objective of this study was to investigate the performance characteristics of
exon-capture technology coupled with massively parallel sequencing for clinical diagnostic
evaluation.
METHODS—We performed a pilot study of four individuals with a variety of previously
identified PCD mutations. We designed a custom array (NimbleGen) to capture 2089 exons from
79 genes associated with PCD or ciliary function and sequenced the enriched material using the
GS FLX Titanium (Roche 454) platform. Bioinformatics analysis was performed in a blinded
fashion in an attempt to detect the previously identified mutations and validate the process.
RESULTS—Three of three substitution mutations and one of three small insertion/deletion
mutations were readily identified using this methodology. One small insertion mutation was
clearly observed after adjusting the bioinformatics handling of previously described SNPs. This
process failed to detect two known mutations: one single nucleotide insertion and a whole exon
deletion. Additional retrospective bioinformatics analysis revealed strong sequence-based
evidence for the insertion but failed to detect the whole exon deletion. Numerous other variants
were also detected, which may represent potential genetic modifiers of the PCD phenotype.
CONCLUSIONS—We conclude that massively parallel sequencing has considerable potential
for both research and clinical diagnostics, but further development is required before widespread
adoption in a clinical setting.
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INTRODUCTION
Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder involving abnormalities
of motile cilia, resulting in a range of manifestations including situs inversus, neonatal
respiratory distress at full term birth, recurrent otitis media, chronic sinusitis, chronic
bronchitis that may result in bronchiectasis, and male infertility.1,2,3 The disorder is
genetically heterogeneous, rendering molecular diagnosis challenging given that mutations
in nine different genes (DNAH5, DNAH11, DNAI1, DNAI2, KTU, LRRC50, RSPH9,
RSPH4A and TXNDC3) account for only ~1/3 of PCD cases.4 DNAH5 and DNAI1 account
for the majority of known mutations, and the other genes each account for a small number of
the remaining cases.5,6 Electron microscopy (EM) can reveal the presence of defective
dynein arms or other axonemal components, and immunohistochemistry can suggest the loss
of specific proteins,4 but in most cases it is impossible to distinguish between patients with
different genetic etiologies. Thus, from a diagnostic standpoint it would be advantageous to
engage in multiplex testing of multiple genes for causative mutations. Such an approach
could also be readily adapted for gene discovery since the known involvement of ciliary
genes in PCD suggests numerous “candidate genes” which are likely to play a role in cases
of PCD without identifiable mutations.
Recent advancements in massively parallel sequencing (so-called “next-generation
sequencing”) are revolutionizing genetic research7–12 and demonstrate potential in clinical
diagnostics.8, 10–11, 13–17 Because of the genetic heterogeneity in PCD, we investigated the
performance characteristics of NimbleGen targeted exon capture followed by massively
parallel sequencing using Roche 454 technology18 for detection of genetic variants in known
and candidate PCD genes. We envision this technology as a hybrid platform capable of
being used in the clinical diagnostic setting as well as in the research setting for those
patients with no mutations in known PCD genes.
In this pilot study, we analyzed four PCD patients in whom disease-causing mutations (three
substitution mutations, three small insertion/deletion mutations, and one whole exon
deletion) were known. One of the patients had only one mutation identified previously, and
we hoped to detect a second deleterious mutation. We expected a high detection rate for
nonsense, small insertion/deletion, and missense mutations that were previously identified in
the patient samples, but we recognized that this approach might fail to detect whole exon
deletions. We anticipated the discovery of “variants of uncertain significance” and “false
positive” results, and we were interested in exploring the reasons for “false negative” results.
The systematic analysis and troubleshooting of such results is a necessary prerequisite to the
implementation of robust genomic analysis in the clinical arena.
MATERIALS AND METHODS
Patients and family members
The patients are enrolled in a study of clinical and molecular aspects of PCD1 approved by
the institutional review board at the University of North Carolina at Chapel Hill (study #
05-2979). DNA was prepared by salt extraction from lymphoblastoid cell lines (patient 475
and patient 1205) or blood samples (patient 998 and patient 1072). DNA quality was
measured by UV spectrometry (A260/280 ratios between 1.84 and 1.89 for all samples) and
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gel electrophoresis. The sample from patient 475 had a small amount of degradation but was
deemed acceptable for use. None of the patients came from consanguineous families.
Exon capture design, enrichment, and sequencing
We designed a custom oligonucleotide microarray (NimbleGen) to capture 2089 exons of 79
genes known to be associated with PCD or candidate genes based on function/expression in
cilia/flagella of human or model organisms (Supplemental Digital Content 1 and 2). The
final targeted region included 510,558 base pairs (95.6%) with an offset of 0 bases, or
520,838 base pairs (97.5%) with an offset of 100 bases. DNA samples from each of the
patients were sent to Roche and subjected to capture and 454 sequencing according to
standard operating procedures. Roche performed mapping, alignment, and variant detection
against the human NCBI Build 36 reference genome using the GS Reference Mapper
software package.19 Samples from patients 475 and 998 underwent an additional round of
sequencing due to concerns about read length in the initial sequencing runs.
Variant analysis
One investigator, blinded to the identity of the previously determined disease-causing
mutations, analyzed all variants within the targeted region for the four patients. The HYDIN
gene on chromosome 16q22 was excluded from our analysis due to the existence of a
paralog mapping to chromosome 1q21 that is not accounted for in the NCBI 36 reference
sequence. Variants identified by GS Reference Mapper are annotated with genomic
coordinates, reference nucleotide, variant nucleotide, number of reads containing the variant
nucleotide, and percentage of reads containing the variant nucleotide. Additional annotations
(if applicable) include the reference amino acid, variant amino acid, reading frame, gene
name, and overlap with a known SNP from dbSNP 130. For identification of possible splice
site mutations, we calculated the distance of each variant to the nearest intron-exon junction
and then selected variants occurring within the last two nucleotides of an exon and first five
nucleotides of the donor intron, or within the last 5 nucleotides of the intron and the first
nucleotide of the acceptor exon. Further characterization of missense mutations was
performed on selected variants using evolutionary conservation and prediction of
pathogenicity with PolyPhen.20,21 PCR amplification and follow-up Sanger sequencing of
newly identified candidate mutations was performed.
Statistical analysis
Tables of variants were organized using Microsoft Excel. Statistical analysis and graphing
was performed using GraphPad Prism (version 5.0b).
RESULTS
Previous characterization of disease-causing mutations in PCD patients
Our group has performed extensive analysis of selected genes in PCD patients and family
members. For the current study, four previously characterized patients were selected based
on qualitatively different types of mutations in three PCD genes (Summarized in Table 1).
• Patient 475: Sanger sequencing of DNAH11, WDR63, RSHL1, RSPH3, RSPH4A,
DNAH5, and selected exons of DNAI1 revealed compound heterozygous
mutations in DNAH5: a missense mutation in the last base of an exon leading to a
splicing defect, and a 21 bp deletion causing an in-frame deletion of 7 amino acid
residues.
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• Patient 998: Sanger sequencing of the entire coding regions of DNAH11, DNAH5
and DNAI1 identified only one mutation in DNAH11, a 4 bp deletion leading to a
frameshift.
• Patient 1072: Sanger sequencing of DNAH5 and DNAI1 revealed compound
heterozygous nonsense mutations in DNAI1 resulting in premature truncation.
• Patient 1205: Analysis of DNAH11 and selected exons of DNAH5 revealed
compound heterozygous mutations in DNAH5: one single base insertion leading to
a frameshift detected by Sanger sequencing and a deletion of exon 62 detected by
multiplex ligation-dependent probe amplification (MLPA).
Exon Capture, High-throughput Sequencing, Mapping, and Variant Identification
Patient DNA was enriched for 2089 exons from 79 known or predicted PCD genes, using a
custom NimbleGen oligonucleotide capture array. Roche GS FLX Titanium massively
parallel sequencing of the enriched material yielded 760,738 – 1,174,723 high quality reads
encompassing 249,757,548 – 363,712,243 high quality bases per patient (see Tables,
Supplemental Digital Content 3 and 4). After mapping, >99.8% of the targeted region was
covered in each patient and >97.7% of the targeted region was covered at >10-fold depth.
Weighted unique mean depth of coverage for the targeted region was 39x–89.2x. Thus, the
coverage should have been adequate to reliably detect germline variants within the vast
majority of targeted regions. There was an average of 538 variants per patient within the
510,558 bp targeted exome region (~1 variant per kb of targeted genome). Roche considers
variants observed in 15–85% of unique reads to be heterozygous, and the GS Reference
Mapper algorithm matches variants to dbSNP version 130. Using these criteria, there were
32–53 novel variants detected per patient sample (Table 2).
Identification of Candidate Disease-Causing Mutations
Since a platform such as this one could eventually be employed in a clinical diagnostic
setting, we attempted to develop an analytic process compatible with the workflow of a
typical molecular diagnostic laboratory, in which variants meeting the following criteria
would be considered potentially causative: (i) detected in >15% of reads, (ii) not
overlapping with an annotated SNP, (iii) predicted to be truncating (premature stop/
frameshift/splice-site disruption) or altering an amino acid, and (iv) presence of two
mutations in one gene, consistent with autosomal recessive inheritance (summarized in
Table 2). While such a scheme would miss rare mutations in regulatory regions or splice
enhancer sequences, it would be expected to identify the majority of clinically relevant
mutations. Variants identified in the initial workflow are further detailed in Table 3.
Patient 475—The initial blinded approach identified both of the previously characterized
disease-causing mutations in DNAH5. The heterozygous 21-bp deletion in the DNAH5 gene
was present in 57% of the reads. The second mutation in DNAH5 was observed in 52% of
sequence reads and consisted of a substitution that changes a methionine residue to leucine
and involves the last nucleotide of the exon, thus disrupting a canonical splice donor
sequence.
This individual had three other genes (RSPH4A, DNAH10, and LRRC50) each with two
novel variants. Both RSPH4A and LRRC50 have been associated with PCD,22,23 while
DNAH10 is an inner arm dynein heavy chain24 but has not been extensively analyzed in
PCD patients. The two RSPH4A variants were both single base insertions that would cause a
frameshift, but were observed in a low percentage of reads. Interestingly, previous analysis
of the RSPH4A gene by Sanger sequencing had identified three common polymorphisms in
this patient but no evidence for the putative novel insertions, indicating that they are likely
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false positive results of 454 sequencing. One of the variants in DNAH10 changed a highly
conserved arginine to tryptophan. The other variant altered an evolutionarily non-conserved
histidine to tyrosine and was also observed in one other patient, suggesting that it is likely
benign. The two variants in LRRC50 were both observed in a low percentage of reads and
were located in a short region of low complexity sequence (CCCCACCACCCCCGCCACC)
within a simple tandem repeat, suggesting that they are sequencing artifacts.
Heterozygous variants of uncertain significance were identified in nine other genes
(DNAH14, DNAH6, SPEF2, DNAH11, DYNC2H1, DYNC1H1, CCDC114, RSPH1, and
RPGR). One of these (DNAH6) was an insertion detected in 16% of sequence reads that was
not detected on subsequent Sanger sequencing.
Patient 998—This patient was the only one in whom only a single disease-causing
mutation had been previously identified – a 4-bp deletion in the DNAH11 gene associated
with PCD and normal axonemal ultrastructure.25 It was therefore hoped that two deleterious
mutations would be identified in DNAH11, or in another known or candidate PCD gene.
The initial blinded analysis failed to identify the known 4-bp deletion mutation in DNAH11
previously detected by Sanger sequencing. The only gene identified as having possible
heterozygous variants was DNAH9, a candidate gene for PCD.26 One DNAH9 variant was a
single base insertion observed in 18% of sequence reads, but it was not detected on Sanger
sequencing. The other DNAH9 variant changes an arginine residue to glutamine, but
glutamine is observed at this site in other species, suggesting that the variant is benign.
Together, these results argue strongly against DNAH9 as the cause of PCD in this
individual.
Two dynein heavy chain genes (DNAH3 and DNAH6) demonstrated novel homozygous
variants. The DNAH3 variant changes an arginine residue to glutamine, but several species
have a glutamine at this position indicating that it is unlikely to be deleterious. The DNAH6
variant changes valine to alanine, but is again poorly conserved; in addition, this variant was
also detected in the homozygous state in patient 1205. Therefore, both of these homozygous
variants most likely represent benign SNPs.
Since some known disease-causing mutations are present in the dbSNP database,27 we
reconsidered all coding variants in this individual, regardless of whether they were annotated
as overlapping with a previously described SNP. In doing so, we recognized the previously
detected 4-bp frameshift deletion in DNAH11, clearly present in 53% of the reads. This
variant had been annotated as overlapping with SNP rs72657376 and was therefore
eliminated from consideration in the initial analytic scheme. This false negative represents a
bioinformatics failure, since the use of dbSNP data as an analytic filter caused us initially to
miss this mutation. Further analysis of DNAH11 revealed several other known SNPs but no
nonsense or likely splice site mutations. Thus, after adjusting the analytic scheme (albeit in a
post hoc fashion) we were ultimately able to identify the 4-bp deletion but no other likely
disease-causing mutations in DNAH11.
Four additional genes (CCDC63, DNAH2, DNAH10, and RSPH1) were found to contain
novel heterozygous missense variants. In DNAH10 and RSPH1 the affected amino acids
were poorly conserved among other species and the variants were both present in patient
475, suggesting that they are likely to be benign. The variant in the CCDC63 gene also
affects a poorly conserved amino acid. However, we were intrigued by a novel heterozygous
missense variant in DNAH2 (chr17:7677205 T>A), altering a highly conserved valine
residue to aspartic acid predicted by PolyPhen to be possibly damaging. This variant was not
observed in any of the three other patients. We therefore considered whether the patient’s
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phenotype could be due to digenic inheritance in this case (Figure 1). Testing of family
members revealed that the DNAH11 mutation was inherited from the patient’s father, and
the DNAH2 variant was inherited from the patient’s mother. Among the three unaffected
siblings, the sister carries only the DNAH11 mutation, a brother carries only the DNAH2
variant, and another brother is wild-type at both loci. The familial segregation is consistent
with the possibility of digenic inheritance, although further studies will be required to
establish this with certainty.
Patient 1072—The initial blinded analysis revealed two heterozygous nonsense mutations
in the DNAI1 gene, which has been previously associated with PCD.28 These were the
precise disease-causing mutations that had previously been identified by Sanger sequencing.
In addition, two novel heterozygous variants in the dynein heavy chain gene DNAH8 were
identified. One of the DNAH8 variants predicts a change of a histidine residue to arginine,
which is observed at this position in numerous other species and was predicted by PolyPhen
to be benign. The other DNAH8 variant changes a threonine residue to methionine and was
predicted by PolyPhen to be probably damaging. Both variants were confirmed by Sanger
sequencing but were found to have been inherited in cis from the mother, whereas the father
was wild-type at both positions. Thus, only one allele of DNAH8 is affected by these
changes. This individual also had heterozygous missense mutations of highly conserved or
invariant amino acids in several other dynein heavy chain genes (DNAH2, DNAH7,
DNAH9) and Tektin-2 (TEKT2), which encodes a protein that is coassembled with ciliary
and flagellar microtubules and may play a role in asthenozoospermia.29
Patient 1205—Neither deleterious mutation previously identified in this patient (a large
exonic deletion and a single nucleotide insertion in DNAH5) was detected by massively
parallel sequencing in our established analytic scheme.
The initial blinded analysis identified only one gene, SPAG17, as having two candidate
variants. The first of these variants changes a methionine to isoleucine and was predicted by
PolyPhen to be benign, while the second variant changes a threonine residue to asparagine
and was predicted by PolyPhen to be damaging. The SPAG17 gene encodes an orthologue
of Chlamydomonas PF6, a component of the flagellar central apparatus.30 Mutations of the
Chlamydomonas ortholog cause flagellar paralysis, but phenotypes have not been reported
in humans or mice. Sanger sequencing confirmed the presence of both variants, but their
clinical significance is uncertain.
This individual had eleven other genes with a single heterozygous novel variant, including
four dynein heavy chain genes (DNAH2, DNAH3, DNAH8, and DNAH10) and a gene
associated with intraflagellar transport (IFT172). In addition, the DNAH6 variant that was
detected in patient 998 was observed in 100% of the reads in this individual. Of the eleven
novel heterozygous variants, five were single base insertions that would be predicted to
cause a frameshift, but all five were present in <25% of the sequence reads. We selected
four of these variants (IFT172, SPEF2, DNAH8, and LRRC50) for confirmation by Sanger
sequencing and none of them were confirmed. The clinical significance of the remaining
heterozygous missense variants remains uncertain at this time.
Having failed to identify likely disease-causing mutations in this individual, we unblinded
the analysis and attempted to find the two mutations in DNAH5 previously discovered
through Sanger sequencing and MLPA. Given that exon capture is non-quantitative, we did
not necessarily expect to find the exon deletion using this platform, and indeed, upon
examining sequence-based data and depth of coverage across all exons, we could not detect
any evidence of the exon deletion (see Text and Figure, Supplemental Digital Content 6).
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However, we were surprised that the insertion mutation in DNAH5 (c.13458_59 insT) was
not identified, even among low-quality variants that failed to meet the “high confidence”
standards. This mutation has been observed in multiple families and may represent a founder
mutation.5 The DNAH5 cDNA is transcribed from the minus strand, and the c.13458_59
insT mutation localizes to a stretch of 7 adenine (7A) nucleotides on the plus strand of the
reference genomic sequence (chr5:13,754,426-13,754,432). Thus, the c.13458_59 insT
mutation should result in 8 adenines (8A) at this position.
Based on previous reports regarding the deficiency of 454 sequencing in regions containing
short homopolymers,31 we hypothesized that the number of adenine residues in different
reads at this position should follow a normal distribution around the “true” number. We
therefore made local alignments of sequence reads (Figure 2A) mapping to this location in
all four patients, tabulated the number of adenine nucleotides in each read, and compared the
proportion of reads containing 5, 6, 7, 8, 9, or 10 reads between each patient (Figure 2B).
The sequence data for patients 475, 998, and 1072 were consistent with a homozygous 7A
genotype, while the sequence data for patient 1205 suggested a heterozygous 7A/8A
genotype (Figure 2C), consistent with the prior Sanger sequencing results. Thus, the
massively parallel sequencing data supports the presence of a mutant 8A allele at this
position when analyzed in a post hoc manner, but the GS Reference Mapper variant
detection algorithm did not identify it prospectively.
Raca and colleagues reported a similar problem with 454 sequencing in a pilot study of
massively parallel sequencing for ocular birth defects.32 These authors reported an initial
failure, also using the GS Reference Mapper software, to detect a single base deletion within
a stretch of 7 guanine nucleotides in the PAX2 gene. However, they were able to
demonstrate the presence of the deletion using two different software packages (CLC
Genomic Workbench and NextGENe). We likewise utilized NextGENe to independently
assemble the raw sequence reads and call variants, and indeed the heterozygous insertion of
adenine was recognized at this location (data not shown). However, this increased sensitivity
came at the cost of greatly increasing the number of putative single nucleotide insertions and
deletions. For instance, using default settings, NextGENe called 5 or more deletion variants
in the coding regions of several genes (observed in >25% of reads and in some cases ~50%
of reads) that were not called by 454’s suite and which occurred in the immediate context of
homopolymer stretches, strongly suggesting that they are false positives.
Analytical sensitivity and specificity of exon capture followed by massively parallel
sequencing
An important potential limitation of this approach is that it may be prone to both false
positive and false negative results. This was clearly the case with the four patient samples
we analyzed. In the course of evaluating novel variants, we used Sanger sequencing to
follow up 16 variants identified by 454 sequencing. All 8 of the putative novel single base
insertion variants, observed in 15–24% of sequence reads, were determined to be false
positives of 454 sequencing based on the negative results of confirmatory Sanger
sequencing. In contrast, Sanger sequencing confirmed all 8 novel missense variants,
observed in 41–56% of sequence reads.
As we inspected the next-generation sequencing data as a whole, it became clear that a large
number of putative novel small insertion/deletion variants were observed in fewer than 25%
of the 454 sequence reads and that this might be a useful signal for flagging possible false
positive results. To further explore this phenomenon, we analyzed the percentage of
sequence reads in which different types of variants were identified (Figure 3). We noted that
insertions and deletions were likely to be detected in a lower percentage of reads than single
base substitutions, which clustered near 50% and 100% of reads, as would be expected for
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heterozygous or homozygous variants, respectively. Putative “novel” (not annotated in
dbSNP) insertion/deletion variants were much more frequently observed in fewer than 25%
of sequence reads compared to “known” (previously annotated in dbSNP) insertion/deletion
variants or “novel” substitution variants (Figure 3A). Although there were no dramatic
differences between the types of variants in terms of total number of sequence reads (Figure
3B), higher read depth was associated with tighter clustering of “known” dbSNP variants
near 50% or 100% of the reads (Figures 3C and 3D), demonstrating the greater precision
that can be achieved with higher depth of coverage. Similarly, “novel” substitution variants
tended to cluster near 50% or 100% of the reads, with the exception of four variants
observed in fewer than 15% of reads that were thus called homozygous wild-type (Figure
3E). In contrast, the putative “novel” insertion/deletion variants displayed a completely
different pattern in which there was no direct relationship between the read depth and the
percentage of reads containing the variant (Figure 3F). As noted above, Sanger sequencing
did not confirm any of the 8 putative “novel” insertion/deletion variants detected by 454
sequencing. Thus, the accuracy of 454 sequencing for detection of small insertion/deletion
variants is not ideal, especially for “novel” insertion/deletion variants identified in fewer
than 25% of sequence reads.
Since the four patient samples were previously subjected to extensive Sanger sequencing of
PCD-associated genes (DNAH5, DNAH11, DNAI1, WDR63, RSPH3/RSHL2, RSPH4A/
RSHL3, RSPH6A/RSHL1), many benign sequence variants were known to be present in
addition to the presumptive disease-causing mutations (see Table, Supplemental Digital
Content 7). We used this additional information to analyze the sensitivity of our targeted
exome massively parallel sequencing approach for detection of sequence variants. Of the
119 benign variants that had previously been found within the exon-targeted region, 114
were also identified with the expected zygosity using massively parallel sequencing. Four of
the discrepancies (three single base substitutions and one 2-bp deletion) were found to be
homozygous wild-type when reanalyzed by Sanger sequencing and thus were determined to
be false positive calls by the previous automated Sanger sequencing. The remaining variant
was a complex alteration in the region of an oligo-dT tract near the end of an intron of
WDR63 (hg18; chr1:85,346,294-85,346,301). Prior Sanger sequencing identified one allele
with a single C insertion and another allele with a CT insertion, immediately preceding the
oligo-dT tract. Massively parallel sequencing correctly detected the homozygous C insertion
(rs11427716) but not the additional heterozygous T insertion. This result further
demonstrates the difficulties posed by homopolymer tracts for 454 sequencing.
DISCUSSION
Targeted exome massively parallel sequencing has great potential for both research and
clinical use. Based on work by Ng and colleagues with whole exome sequencing, each
individual likely has 6–12 genes with two predicted damaging mutations that are not present
in control populations (dbSNP, HapMap).9 In a clinically distinctive autosomal recessive
disorder with only one disease locus, discovery of the disease gene by whole exome
sequencing could require as few as three or four unrelated individuals.7 However, due to the
genetic heterogeneity of PCD (and many other genetic disorders), a much larger number of
individuals might need to be analyzed in order to identify genes in common among subsets
of such patients. We are currently engaged in whole-exome sequencing of additional PCD
patients whose mutations remain unidentified (M.A.Z. and M.R.K.). However, while the
research implications of next-generation sequencing are clear, use of this emerging
technology for clinical diagnostic testing still requires careful calibration.
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Detection of known mutations associated with PCD
In this work we conducted a pilot study of four patients with clinical features consistent with
PCD and with previously identified mutations in genes associated with PCD. We
specifically chose samples with qualitatively different types of mutations occurring in
different genes in order to determine whether targeted exome capture combined with next-
generation sequencing could identify different classes of mutations. The exome capture of
79 known or candidate PCD genes, followed by massively parallel sequencing using 454
technology and structured analysis, identified five of the seven known mutations associated
with PCD in three of the four patients, including one patient (#475) with two previously
identified mutations in the dynein heavy chain gene DNAH5 (a nucleotide substitution
resulting in a splice site alteration and a 21 bp deletion) and another patient (#1072) with
two different single nucleotide nonsense mutations in the dynein intermediate chain gene
DNAI1. In the third patient (#998), previous analysis had identified only one disease-
causing mutation in DNAH11 (a 4-bp frameshift deletion). This mutation was incorrectly
excluded by the initial analytic scheme due to its annotation as a known SNP, but was
correctly identified after a simple adjustment of the handling of annotated SNPs. In the
fourth patient (#1205), the single base frameshift insertion could only be demonstrated
retrospectively with analysis of sequence reads, but the exonic deletion was not detected.
Variants of Uncertain Clinical Significance
A number of other heterozygous and homozygous novel variants were identified in the four
patients. Although these variants are of unknown clinical significance, it is tempting to
speculate that some could play a role in the PCD phenotype, acting as genetic modifiers.
Further massively parallel sequencing of a large number of PCD patients with known
deleterious mutations could lend further insight into the roles of putative disease-modifying
variants.
The patient in whom a single disease-causing mutation in DNAH11 had previously been
identified (#988) was found in this study to have a missense variant in DNAH2. Mutation
profiling of DNAH2 has not been carried out in PCD patients, but mutations of the
Chlamydomonas ortholog (Dhc10) alter flagellar motility.33 The DNAH2 variant affected a
highly conserved amino acid residue that was predicted to be damaging, and family
segregation analysis was consistent with the possibility of digenic inheritance. Although this
finding does not prove that digenic variants of DNAH11 and DNAH2 can result in
pathogenicity, digenic inheritance has been previously hypothesized in PCD34 and there is
precedent for triallelic inheritance in a different ciliopathy, Bardet-Biedel syndrome.35 It is
worth noting that DNAH11 encodes an outer dynein arm protein while DNAH2 encodes an
inner dynein arm protein; since both DNAH11 and DNAH2 proteins are components of the
ciliary dynein arms, which require complex protein interaction for motility, it is thus
possible that haploinsufficiency of these two different genes could result in reduced ciliary
function without a structural defect discernable by EM. We speculate that this patient’s
phenotype could be due to the combinatorial effects of mutations in DNAH11 and DNAH2.
However, it is also possible that there simply remains an undetected mutation in a regulatory
element, promoter, or intron of DNAH11 or DNAH2, or biallelic mutations in a gene not
present among the 79 genes analyzed here.
Finally, it is worth noting in this context that massively parallel approaches such as whole-
exome and whole-genome sequencing will result in the identification thousands of protein
coding variants in each individual, any of which could potentially impact disease (either
directly as a disease-causing mutation or as a genetic modifier), rendering the determination
of clinical significance exceedingly complex with respect to various combinations of
mutations. For example, if alternative inheritance patterns such as digenic inheritance are
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considered, the number of different possibilities quickly becomes astronomical when
variants are simultaneously detected in hundreds or thousands of genes. This will be a major
challenge faced by molecular diagnosticians and clinicians in the future as multiplex gene
sequencing is more broadly applied.
Performance and limitations of targeted exome massively parallel sequencing
In addition to the previously identified disease-causing mutations, we analyzed 119 benign
variants previously identified in the four patients by automated Sanger sequencing. Of these,
targeted exome massively parallel sequencing correctly identified 114 variants and revealed
4 of these putative variants to be false positive results of the Sanger sequencing. Thus, the
final 454 and Sanger sequencing results were in agreement for 114 of 115 benign
polymorphic variants and >99% of wild-type reference calls. Including the six previously
identified small deleterious mutations, we calculate a sensitivity of 98.3% (119/121) for
detection of sequence variants by exon capture followed by 454 sequencing. The vast
majority (>90%) of the polymorphisms studied here were single nucleotide substitution
variants, so this result primarily confirms that 454 sequencing has high sensitivity and
specificity for the detection of substitution mutations.
All of the variants in which there was discordance between the final 454 and Sanger
sequencing results were small insertions or deletions. This drawback is inconvenient but not
devastating for researchers, who expect and tolerate a certain level of error, but it is of
particular importance for clinical diagnostic testing. Small insertion and deletion mutations
make up ~22% of the ~100,000 known mutations in the human gene mutation database
(http://www.hgmd.cf.ac.uk/), and inability to reliably identify this class of mutations would
be a major limitation of adopting 454 sequencing for clinical diagnostic testing.
In an empirical study using a library of reference templates, Huse and colleagues found that
insertions and deletions were the most common errors observed with 454 pyrosequencing,31
comprising 63% of all sequence errors. These calculations were based on individual reads,
whereas variant detection is based on the percentage of mapped reads that contain the
variant, so it is unclear how this error rate might translate directly to inaccurate detection of
insertion/deletion variants. In our experience, the majority of putative novel (not previously
reported in dbSNP) insertion/deletion variants were observed in fewer than 25% of the
sequence reads and this phenomenon appeared to be independent of the depth of coverage.
Sanger sequencing did not confirm any of the eight putative novel single nucleotide
insertions that we analyzed. Restricting analysis only to variants detected in greater than
25% of sequence reads greatly improved the specificity of this approach without affecting
sensitivity (data not shown).
One explanation for the detection of sequence variants in fewer than 25% of reads could be
the existence of pseudogenes not currently annotated in the reference genome but
nevertheless contributing to the material being sequenced (eg. HYDIN; see Text and Figure,
Supplemental Digital Content 8). However, in this case one might expect recurrent
substitution and insertion/deletion variants affecting the same few genes (those with
previously undiscovered pseudogenes or paralogous copies), and for the same variants to be
present in more than one individual. None of these were the case in our experience,
suggesting that false positive insertion/deletion identification is largely inherent to 454
sequencing technology. Thus, many (perhaps most) of the novel insertion/deletion variants
detected in <25% of 454 sequence reads appear to be artifacts of the biochemistry,
bioinformatics, or both.
In our study, a single base insertion mutation in patient #1205 was only identified
retrospectively by demonstrating that the sequence data was consistent with the presence of
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the heterozygous insertion in comparison to the three other patients. This false negative
result thus represents a combined platform and bioinformatics failure. Indeed, the 454
bioinformatics pipeline appears to employ proprietary models to compensate for the
imprecision of pyrosequencing with regard to homopolymers, perhaps explaining why the
true deleterious insertion mutation in patient #1205 was not called by GS Reference Mapper
but was called by NextGENe. As noted above, the increased sensitivity of the NextGENe
analysis came at the unacceptable cost of lower apparent specificity, since a much higher
number of putative small insertion/deletion variants were detected in the vicinity of
homopolymer stretches. Since all possibly deleterious variants will require confirmation
with clinical Sanger sequencing, at least in the short term, follow-up sequencing could be
very costly or impractical with a high false positive rate for novel insertion/deletion variants.
It was not entirely unexpected that the approach described here was unable to detect a whole
exon deletion in the DNAH5 gene in patient 1205, since targeted exon capture is not
designed to detect large deletions. We attempted to uncover evidence for the whole exon
deletion in structural variant alignments and analysis of sequence read depth, but were
unable to find such confirmation. Variability in the depth of coverage between exons and
between samples in our study appears to have been too high to reliably detect changes in
exon copy number using non-quantitative exon capture methods. Interestingly, while this
manuscript was under review, another group published a report of a similar approach to
detection of inherited mutations for breast and ovarian cancer, in which deletions or
duplications encompassing single or multiple exons were, in fact, accurately detected.36
Possible reasons for Walsh and colleagues’ success include differences in platforms or
technical aspects of the exon capture process, a greater than 10-fold higher mean depth of
coverage (~1200x), and a larger number of samples between which comparisons could be
made.
Conclusions
Massively parallel sequencing has already proven successful in research settings and its
adoption for clinical diagnostic testing appears to be inevitable, particularly as the costs per
base continue to decrease. Nevertheless, clinical tests based on next-generation sequencing
present special challenges not germane to research applications and will need careful
validation to assess the performance characteristics of this new technology and to optimize
the analytical sensitivity and specificity. Next-generation sequencing platforms may have
inherent differences in detection of diverse types of variants,37,38 so any clinical applications
based on next-generation technologies will need to be validated on different types of known
reference mutations to determine their performance characteristics. Analytic software for
clinical diagnostic approaches will also need to be optimized for detection of different types
of mutations. Reliance on dbSNP as a bioinformatics filter appears to be problematic, given
that some rare deleterious mutations are contained among the many benign variants. We
expect that as whole-exome and whole-genome sequencing are carried out in large numbers
of patients and control subjects, an approach will evolve towards using information about
the population frequency of a variant, rather than its presence or absence in a database, as a
key filter for evaluating the likely clinical implications of a given variant. We conclude that
exon-capture followed by massively parallel sequencing has considerable potential in
clinical diagnostics, but deficiencies will need to be quantified and rectified before
widespread adoption in a clinical setting.
SDC 1. Table containing genes targeted for exon capture (.pdf)
SDC 2. File containing genomic coordinates of targeted exons and exon capture probes used
in this study (.bed file)
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SDC 3. Table containing sequence read characteristics for each patient sample (.pdf)
SDC 4. Table containing summary of GS FLX Titanium sequencing and mapping (.pdf)
SDC 5. Text and Figure detailing attempts to detect a whole exon deletion (.pdf)
SDC 6. Table containing benign polymorphisms previously identified by Sanger sequencing
(.pdf)
SDC 7. Text and Figure showing that variants detected in the HYDIN gene have a distinct
pattern with respect to the percentage of sequence reads containing the variants (.pdf)
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Family segregation analysis supports the possibility of digenic inheritance of DNAH11
and DNAH2 mutations in patient 998
A patient with a phenotype consistent with PCD (II-1) was previously found to have a single
mutation in DNAH11, which encodes a component of the outer dynein arm. Targeted exome
sequencing found no additional possible disease-causing mutations in DNAH11 but
identified a heterozygous missense mutation of a highly conserved residue of DNAH2,
which encodes a component of the inner dynein arm. Family segregation analysis revealed
that the DNAH11 mutation was inherited from the patient’s father (I-1), while the DNAH2
mutation was inherited from the patient’s mother (I-2). Furthermore, the three unaffected
siblings were heterozygous for only the DNAH2 allele (brother II-2), heterozygous for only
the DNAH11 allele (sister II-4), or wild-type for both alleles (brother II-3).
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Figure 2. Sequence analysis favors the existence of a heterozygous insertion in patient 1205
A. Local alignment of selected sequence reads from patient 1205 in the region containing a
single nucleotide insertion (hg18; chr5:13,754,404 – 13,754,447). The top line of the
alignment represents the NCBI 36 reference sequence at this location. Gaps introduced into
the alignment are represented by a “-“. Yellow highlights the stretch of 7 adenine (7A)
nucleotides where the insertion should result in 8 adenine (8A) nucleotides. B. The
proportion of reads containing 5, 6, 7, 8, 9, or 10 adenine nucleotides reveal a clear
difference in patient 1205. Patients 475, 998, and 1072 act as “controls” since they are
homozygous for reference 7A alleles. The highest proportions of reads in these samples
were 7A, with Gaussian distributions (R2 > 0.998) having peaks at approximately 6.75
(6.607, 6.778, and 6.842), consistent with a homozygous 7A genotype at this position. In
contrast, the number of adenine residues in the sample from patient 1205 ranged from 5 to
10, with a Gaussian distribution (R2 = 0.964) that was broader than the first three patients
and had a peak at 7.54. C. When compared to simulated genotypes, the distribution from
patient 1205 most closely resembles the heterozygous distribution. The distributions of the
three “control” samples were averaged to obtain a simulated homozygous 7A distribution
(SIM-7A). This distribution was shifted to the right to generate a simulated homozygous 8A
distribution (SIM-8A). The SIM-7A and SIM-8A distributions were averaged to simulate
the expected distribution in an individual heterozygous for 7A and 8A (SIM-7A/8A Het).
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Figure 3. Small insertion/deletion variants are observed in distinct proportions of sequence reads
A. Variants were separated by class and whether they were novel or previously reported in
dbSNP, and plotted according to the percentage of sequence reads in which the variant was
observed. Dashed lines represent 25% and 75% of sequence reads. Substitution variants
largely clustered near 50% or 100% of sequence reads as would be expected for
heterozygous or homozygous variants, respectively. Known insertion/deletion variants (Ins/
Del) also tended to cluster near 50% or 100% of sequence reads. However, novel small
insertion/deletion variants had a much wider distribution with a significant proportion of
variants detected in fewer than 25% of the sequence reads. B. The depth of coverage,
defined by the number of sequence reads in the alignment for a given variant, is shown for
the different types of sequence variants. No obvious differences were observed between the
classes of variants in terms of the total depth of coverage. C-F. Known substitutions, known
insertions/deletions, novel substitutions, and novel insertions/deletions were plotted
according to the total read depth and the percentage of reads in which the variant was
observed. The novel insertion/deletion variants clearly follow a distinct pattern, with a large
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proportion of the variants detected in fewer than 25% of sequence reads but no clear
relationship between depth of coverage and the percentage of reads in which the variant was
observed.
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Table 2
Candidate mutations identified through an initial blinded analysis of variant data
Pt. 475 Pt. 998 Pt. 1072 Pt. 1205
Total HC Variants 18,042 19,877 12,332 10,560
 - In Region (-HYDIN) 521 435 449 456
 - >15% of reads 515 423 443 435
  - Novel 51 31 28 49
   - Intronic 29 21 16 31
   - Synonymous 4 2 3 5
   - Missense 10 7 7 8
   - Nonsense 0 0 2 0
   - Small ins/del 7 1 0 4
  - Near splice site 1 0 0 4
  - Candidate mutations 17 8 9 16
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